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Abstract
Background: The nuclear inclusion a (NIa) protease of turnip mosaic virus (TuMV) is responsible for the processing of the
viral polyprotein into functional proteins. NIa was previously shown to possess a relatively strict substrate specificity with a
preference for Val-Xaa-His-GlnQ, with the scissile bond located after Gln. The presence of the same consensus sequence,
Val
12-His-His-Gln
15, near the presumptive a-secretase cleavage site of the amyloid-b (Ab) peptide led us to hypothesize that
NIa could possess activity against Ab.
Methodology/Principal Findings: Western blotting results showed that oligomeric as well as monomeric forms of Ab can
be degraded by NIa in vitro. The specific cleavage of Ab was further confirmed by mass spectrometry analysis. NIa was
shown to exist predominantly in the cytoplasm as observed by immunofluorescence microscopy. The overexpression of NIa
in B103 neuroblastoma cells resulted in a significant reduction in cell death caused by both intracellularly generated and
exogenously added Ab. Moreover, lentiviral-mediated expression of NIa in APPsw/PS1 transgenic mice significantly reduced
the levels of Ab and plaques in the brain.
Conclusions/Significance: These results indicate that the degradation of Ab in the cytoplasm could be a novel strategy to
control the levels of Ab, plaque formation, and the associated cell death.
Citation: Han H-E, Sellamuthu S, Shin BH, Lee YJ, Song S, et al. (2010) The Nuclear Inclusion a (NIa) Protease of Turnip Mosaic Virus (TuMV) Cleaves Amyloid-b. PLoS
ONE 5(12): e15645. doi:10.1371/journal.pone.0015645
Editor: Rafael Linden, Universidade Federal do Rio de Janeiro, Brazil
Received July 26, 2010; Accepted November 19, 2010; Published December 20, 2010
Copyright:  2010 Han et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant from the National Research Foundation of Korea (No. 2009-0085747), a grant from the Global Research Laboratory
Program (M6-0605-00-0001) funded by the Korean government (MEST), and a grant from the ‘‘Systems biology infrastructure establishment grant’’ provided by
Gwangju Institute of Science and Technology (GIST).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: wjpark@gist.ac.kr
Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorders which affects approximately twenty four million people
worldwide, and it is the most common form of dementia among
older people. AD is characterized by progressive memory
impairment and cognitive dysfunction. A distinct hallmark of
AD is the deposition of amyloid plaques which are mainly
composed of amyloid b (Ab) of 40, 42, and 43 amino acids in
length. Ab is produced by the sequential cleavage of the amyloid b
precursor protein (APP) by b- and c-secretases[1,2].
Ab can exist in different forms such as monomers, oligomers
(dimer, trimer, and tetramer), proto-fibrils, and fibrils, and these
different conformational states are related to its toxicity. Oligomeric
Ab was shown to be approximately 10- and 40-fold more cytotoxic
than fibrillar and monomeric Ab,respectively[3].Arecentreportalso
found that dimeric Ab are 3-fold more toxic than monomeric Ab,
and that trimeric and tetrameric Ab are up to 13-fold more toxic[4].
Although Ab unquestionably plays a causative role in AD,
the underlying mechanisms by which it contributes to the
development of this disease are still controversial. It is widely
accepted that Ab exerts its pathological activity extracellularly. In
pathological AD brains, Ab is secreted into the extracellular space
forming amyloid plaques[5]. When added into the culture media,
Ab can induce cell death in vitro in a variety of cell types[3,4,6].
However, accumulating evidence suggests that intracellular Ab
activity is also critical for the development of AD. Several authors
have reported the intracellular localization of Ab in the brain
tissues of post-mortem AD patients and in transgenic AD
mice[1,7,8]. A closer examination with electron microscopy and
immunocytochemistry revealed that Ab is present in diverse
subcellular organelles in neuronally differentiated P19 cells,
including early endosomes, trans-Golgi network, rough endoplas-
mic reticulum, outer mitochondrial membrane, and nuclear
envelope[9]. In a triple transgenic AD mouse model, early cogni-
tive impairments correlated with the accumulation of intracellular
Ab in the hippocampus and amygdala, without the apparent
deposition of amyloid plaques or neurifibrillary tangles[10].
Intracellular Ab was also shown to induce p53-dependent
neuronal cell death[11,12] through the impairment of mitochon-
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directed against Ab reduced not only extracellular Ab deposits, but
also intracellular Ab accumulation. Upon dissipation of this
antibody, the re-appearance of the extracellular deposits was
preceded by the accumulation of intracellular Ab. These
observations suggest that a dynamic exchange between intracel-
lular and extracellular Ab exists, and that intracellular Ab serves as
a source of extracellular amyloid deposits, implying a role for
intracellular Ab in the pathogenesis of AD[14,15].
There are currently no methods proven to efficiently remove
accumulated amyloids with improved AD symptoms. Since the
accumulation of Ab is considered to be the most critical single event
in the pathogenesis of AD, a catabolic elimination of Ab from the
brain would be a valuable therapeutic strategy. Several proteases,
including neprilysin (NEP), insulin degrading enzyme, endothelin-
converting enzyme, and uPA/tPA-plasmin, have been identified for
their ability to degrade Ab[16], with NEP being the best-
characterized one. The pharmacological inhibition or genetic
ablation of NEP in mice has been shown to result in an increased
Ab deposition, accompanied by deficits in synaptic plasticity and an
impairment in hippocampus-dependent memory[17,18], while the
viral or transgene-mediated overexpression of NEP reduced Ab
deposition and its associated cytopathology[19,20]. However, it was
recently shown that NEP overexpression did not reduce the
oligomeric Ab levels or improve deficits in learning and memory.
These results appear to suggest that the NEP-dependent degrada-
tion of Ab affected plaques more efficiently than oligomeric Ab[21].
We have previously reported that the nuclear inclusion a (NIa)
protease of Turnip mosaic virus (TuMV) contains a strict substrate
specificity with a preference for Val-Xaa-His-GlnQ, with the
scissile bond located after Gln[22]. Based on the fact that Ab
contains an amino acid sequence, Val-His-His-Gln, in the vicinity
of the presumed a-secretase cleavage site, we tested whether NIa
can cleave Ab. In this study, we show that NIa indeed cleaves
monomeric and oligomeric Ab and that it significantly ameliorates
the Ab-induced cell death in neuronal culture cells and the Ab-
related pathology in transgenic AD mice. NIa might therefore
provide a novel strategy for the clearance of toxic oligomeric Ab
from the brain of AD patients.
Results
Cleavage of monomeric and oligomeric Ab by NIa
We have previously reported that NIa possesses a highly strict
substrate specificity, with its cleavage sites defined by the
conserved sequence motif Val-Xaa-His-GlnQ, in which the
scissile bond is located after Gln. Interestingly, the sequence Val-
His-His-Gln is present in Ab in the vicinity of the presumed a-
secretase cleavage site (Fig. 1A). Based on this finding, we aimed to
determine whether NIa can specifically cleave Ab. For this
purpose, a recombinant NIa protein was expressed in E. coli and
purified to near homogeneity on a chitin bead column (Fig. 1B).
NIa was then incubated with a monomeric Ab preparation for
3 hrs in the presence or absence of the cysteine protease inhibitor,
NEM. Analysis by Western blotting revealed that the monomeric
Ab level was greatly reduced by NIa (Fig. 1C, lane 2 vs. 4), which
was partially reversed in the presence of NEM (Fig. 1C, lane 6).
The results of the densitometry analysis showed that NIa reduced
Ab levels by 64% in the absence of NEM and 33% in the presence
of NEM, suggesting the specific cleavage of monomeric Ab by
NIa. Our findings show that NEM did not completely inhibit NIa
activity, which is consistent with a previous report showing that
mutations of cysteine residues in the catalytic triad of NIa did not
completely abolish its proteolytic activity[23].
We then tested whether NIa is capable of cleaving oligomeric
Ab, which is known to be more toxic than monomeric Ab.
Oligomeric Ab was prepared by incubating a solution of Ab
peptides at 4uC for 36 hrs. As assessed by SDS-PAGE, the
oligomeric Ab preparation contained roughly equal amounts of
monomeric and oligomeric Ab (Fig. 1D, lanes 1, 3, and 5), a
balance that shifted toward an increase in the formation of
oligomeric Ab at the expense of monomeric Ab after an additional
3 hour incubation at 25uC. This is consistent with a previous
report showing that Ab oligomerization was accelerated by an
increase in incubation time and temperature[24]. Under the same
conditions, the amount of oligomeric Ab was greatly reduced by
NIa (lane 4) as quantified by densitomeric assessment, which
showed that only 19% of oligomeric Ab remained. This NIa-
mediated reduction of oligomeric Ab was significantly blocked by
NEM (lane 6) implying that NIa specifically cleaves Ab.
To further analyze the specific cleavage of Ab by NIa, the
cleavage products were analyzed by MALDI-TOF/TOF mass
spectrometry (Fig. 2). The monomeric Ab preparation produced a
single peak without contamination, whereas NIa produced three
contaminating peaks. In the reaction mixture including Ab and
NIa, the peak corresponding to Ab was greatly reduced and two
new peaks were detected (Fig. 2B), with molecular weights of
1,826 Da and 2,704 Da, corresponding to amino acids1–15 and
16–42 of Ab, respectively (Fig. 2A). This result indicates that NIa
cleaves the peptide bond after Gln
15, as expected.
Subcellular localization of NIa
B103 neuroblastoma cells were transformed with an HA-tagged
NIa expression vector and stained with an anti-HA antibody.
Examination with confocal microscopy revealed that NIa was
expressed predominantly in the cytoplasm (Fig. 3A). The trans-
formed cells were fractionated into the particulate (P) and soluble
(S) fractions and subjected to Western blotting (Fig. 3B). While
Oct1 (nuclear marker), VDAC2 (mitochondrial marker), and
cathepsin D (lysosomal marker) were found in the particulate
fraction, HA was colocalized with a-tubulin (cytosolic marker)
exclusively to the soluble fraction. These data suggest that NIa
resides predominantly in the cytosol.
NIa prevents Ab-induced cell death
To test whether NIa possesses activity against Ab within cells,
we generated Ab intracellularly using the plasmid pGFPUb-Ab,
encoding a triple fusion protein of green fluorescent protein (GFP),
ubiquitin (Ub), and Ab. The peptide bond between Ub and Ab is
cleaved quickly by endogenous deubiquitinating enzymes, gener-
ating an equimolar ratio of GFP-Ub and Ab in the cytosol[25].
B103 cells were co-transformed with pGFPUb-Ab and an empty
plasmid, a NIa-expression plasmid, pcDNA-HA-NIa, or a mutant
NIa expression plasmid, pcDNA-HA-mNIa. The NIa mutation
consisted of an Asp to Ala substitution in the catalytic triad. The
cells were then immunostained with the anti-Ab antibody, 6E10
(Fig. 4A and B). The results revealed that the proportion of Ab-
positive cells was 56% of the total of GFP-positive cells in those
cells harboring pGFPUb-Ab and an empty plasmid (Mock),
whereas the ratio sharply declined to 14% in cells harboring
pGFPUb-Ab and pcDNA-HA-NIa (NIa). The observed ratio in
those cells expressing a mutant NIa protease plasmid (mNIa) was
42%, which was not significantly different from that obtained with
an empty plasmid. These data indicate that NIa can degrade
intracellular overexpressed Ab.
To evaluate whether NIa prevents Ab-induced cell death, we
used two different methods, a morphological approach and the
MTT cell viability assay (Fig. 4B and C). Intracellular expression
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death (62% by the morphological assay and 55% by the MTT
assay). This intracellular Ab-induced cell death was almost
completely blocked by co-transfomation with pcDNA-HA-NIa
but it was not affected in cells co-expressing pcDNA-HA-mNIa.
Treatment of B103 cells with exogenous Ab also resulted in a
Figure 1. Cleavage of Ab by NIa. (A) The amino acid sequence of Ab is aligned with the consensus cleavage site of NIa, Val-Xaa-His-Gln. (B) NIa
was purified from E. coli and separated by SDS-PAGE. Lane 1, molecular size markers; lane 2, NIa (10 mg). (C) Monomeric Ab (2.5 mM) was incubated
with NIa (1.5 mM) in the presence or absence of NEM(cysteine protease inhibitor) for 3 hrs at 25uC. The reaction mixture was separated on a Tris-
tricine gel, blotted, and probed with the anti-Ab antibody, 6E10. The density of each Ab band was quantified by densitometry. The band intensities
after 3 hr incubation (lanes 2, 4, and 6) were plotted relative to the band intensities of each sample at 0 hr (lanes 1, 3, and 5). n=4. (D) Oligomeric Ab
(2.5 mM) was incubated with NIa (1.5 mM) in the presence or absence of NEM for 3 hrs at 25uC. The reaction mixture was separated and
immunoblotted with anti-Ab antibody, 6E10. The density of oligomeric Ab bands was quantified by densitometry. The band intensities of oligomeric
Ab after 3 hr incubation (lanes 2, 4, and 6) were plotted relative to the band intensity of the Ab only sample at the 3 hr incubation time point (lane 2).
n=4. Error bars represent SD. *p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0015645.g001
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assay and 38% by the MTT assay), which was inhibited by co-
transfomation with pcDNA-HA-NIa but not by pcDNA-HA-
mNIa co-expression (Fig. 5A and B). It was previously shown that
extracellular Ab is internalized by cell surface receptors and
detected in subcellular organelles such as lysosomes, mitochondria
and cytosol, causing cell death through dysfunction of these
organelles[26–29]. It appears that cytosolic NIa can cleave
internalized Ab, although it is unknown whether NIa and
internalized Ab are co-localized. Nonetheless, our data indicate
that NIa can prevent cell death induced by both intracellularly
expressed and exogenously added Ab.
Lentiviral-mediated overexpression of NIa
Lentiviral vectors expressing NIa and GFP were generated
(Fig. 6A). Human 293T cells infected with Lenti-NIa showed a
strong NIa expression, as assessed by Western blotting with anti-
HA antibody (Fig. 6B). Double transgenic mice (APPswe/PS1dE9)
were stereotaxically injected with 3 ml of Lenti-NIa (1610
8 TU)
into the lateral ventricles. To evaluate the expression of NIa,
immunohistochemistry was performed one month after injection.
The NIa expression was detected in sections of mice injected with
Lenti-NIa compared with the brain sections of control non-
injected mice. The pattern of NIa expression showed a wide
distribution throughout the brain including the cerebral cortex,
Figure 2. Mass spectra of monomeric Ab incubated with NIa. (A) The calculated molecular masses of the expected cleavage products are
shown. (B) Monomeric Ab (2.5 mM) was incubated with NIa (1.5 mM) for 3 hrs at 25uC and analyzed using MALDI-TOF/TOF mass spectrometry. Note
that two peaks corresponding to the Ab cleavage products as well as a peak corresponding to Ab were detected. As controls, NIa and Ab were
analyzed separately. Three minor peaks marked by asterisks represent contamination of the NIa preparation.
doi:10.1371/journal.pone.0015645.g002
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PCR also showed the presence of the NIa transcripts in the Lenti-
NIa-infected brain. The GAPDH signal served as a control and
was equally expressed in all samples (Fig. 6C).
Decreased Ab levels in the brain of APPsw/PS1 transgenic
mice infused with Lenti-NIa
To assess if NIa causes a reduction in the Ab levels in mouse
brains, Lenti-NIa was infused into the lateral ventricles of the
brain of APPsw/PS1dE9 mice at 6.5 months of age. As a control,
equal amounts of Lenti-GFP were infused in the same manner.
The brains were removed one month after injection and the Ab
levels in both soluble (Tris-buffer extractable) and insoluble (FA-
buffer extractable) fractions were measured by ELISA. We found
that the levels of both Ab1240 and Ab1242 were significantly
reduced in both the soluble and insoluble factions of Lenti-NIa-
infused brain when compared to the Lenti-GFP-infused brain
(Fig. 7A). The Lenti-NIa infusion reduced the soluble Ab1240 by
33% in males and by 36% in females, and the insoluble Ab1240 by
24% in males and by 21% in females (Fig. 7A, upper lane). NIa
also reduced the soluble Ab1242 by 38% in males and by 28% in
females, and the insoluble Ab1242 by 33% in males and by 36% in
females (Fig. 7A, lower lane). The reduction of Ab1242 levels in the
male brains was not statistically significant.
Reduced Ab deposition in the brain of APPsw/PS1
transgenic mice infused with Lenti-NIa
Immunohistochemical analysis revealed that the Ab deposition
in the prefrontal cortex, parietal cortex, hippocampus and
piriform cortex was remarkably decreased in the brain infused
with Lenti-NIa in comparison to the brain infused with Lenti-GFP
(Fig. 7B). Quantitative assessment of Ab levels indicated that the
Lenti-NIa infusion reduced the plaques by 58% in the prefrontal
cortex, by 62% in the parietal cortex, and by 59% in the piriform
cortex (Fig. 7C).
Discussion
The generation and accumulation of Ab is the most critical
event in the development of AD, suggesting that the clearance of
Ab could provide a valuable strategy for the treatment of AD.
Although Ab exits in several assembly and aggregation forms,
oligomeric Ab is known to be the most toxic form. Ab is
oligomerized intracellularly soon after it is generated, and these
molecules are then secreted from the cell. Some of the secreted Ab
oligomers enter the cell through selective uptake and subsequently
cause the dysfunction of subcellular organelles, which is associated
with the memory and cognitive decline typically observed in AD
patients[30].
Ab is detected in both intraneuronal cells and in the
extracellular space of AD brains. Recent studies have demonstrat-
ed that intracellular Ab levels decrease as extracellular plaques
start to build up in patients with AD and in AD transgenic mouse
models[10,31]. These results suggest that the accumulation of
intracellular Ab precedes the formation of extracellular Ab
deposits in the progression of the disease. Interestingly, in cells
expressing the AD-associated mutant APP, Ab is kept within the
cells, whereas in cells expressing wild-type APP, Ab is mostly found
to be secreted[32]. In addition, in aged mice carrying mutant
presenilin 1, Ab aggregation is detected within neurons, but it is
absent in the extracellular fluid[33]. The inhibition of proteasome
activity leads to higher levels of Ab both in vivo and in vitro,
suggesting that the proteasome is responsible for the processing of
Ab in the cytosol[25,34,35]. The overproduction of Ab results in
an overload of the proteasome, ultimately leading to an impair-
ment of proteasome activity, a characteristic of AD[36,37]. These
reports support a central role for intracellular Ab in the patho-
genesis of AD.
The enhanced proteosomal activity caused by the plant
polyphenol resveratrol was shown to reduce intracellular as well
as extracellular Ab levels and to prevent neurodegenerative
disorders[38]. Parkin is an E3 ligase which participates in the
ubiquitination of intracellularly expressed Ab. The overexpression
of parkin was found to result in a proteasome-mediated reduction
of Ab levels[39], whereas the knockout of parkin caused an
accumulation of Ab deposits[39,40]. Enhanced clearance of intra-
cellular Ab may therefore prevent plaque formation, secondary
pathology and premature death.
In this study, we show that a plant viral protease, NIa,
specifically cleaves oligomeric as well as monomeric Ab in vitro and
is predominantly localized in the cytosol of neuronal cells. The
expression of NIa in neuronal cells inhibits cell death induced both
by intracellularly expressed and exogenously added Ab.I n
addition, lentiviral-mediated overexpression of NIa in the brain
of AD transgenic mice was found to reduce the levels of Ab
and plaque formation. These data provide additional evidence
Figure 3. Subcellular localization of NIa in B103 neuroblastoma
cells. (A) B103 neuroblastoma cells transformed with pcDNA-HA-NIa
were immunostained with anti-HA antibody and observed under a
confocal microscope. (B) B103 cells transformed with a blank plasmid
(Mock) or pcDNA-HA-NIa (NIa) were fractionated into particulate (P) and
soluble (S) fractions by differential centrifugation. The two fractions
were separated by SDS-PAGE, blotted, and probed with antibodies
against Oct1 (nuclear), VDAC2 (mitochondrial), cathepsin D (lysosomal),
a-tubulin (cytosolic), and HA (NIa).
doi:10.1371/journal.pone.0015645.g003
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PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15645Figure 4. Degradation of intracellular Ab and inhibition of intracellular Ab-induced cell death by NIa. (A) B103 neuroblastoma cells were
cotransfected with pGFPUb-Ab and an empty vector (Mock), pcDNA-HA-NIa (NIa), or pcDNA-HA-mNIa (mNIa). After 48 hrs of incubation, the cells
were immunostained with the anti-Ab antibody, 6E10. (B) The number of Ab-positive cells (red) and GFP-expressing cells (green) were counted under
the microscope and their ratio was calculated. n=6. (C) Cell death induced by intracellular Ab peptide was measured by morphological and MTT
assays. n=6. Error bars represent SD. **p,0.01.
doi:10.1371/journal.pone.0015645.g004
Figure 5. Inhibition of exogenously added Ab-induced cell death by NIa. B103 neuroblastoma cells transfected with an empty vector
(Mock), pcDNA-HA-NIa (NIa), or pcDNA-HA-mNIA (mNIa) were treated with Ab (5 mM) in culture media for 48 hrs. Cell death was measured by
morphological and MTT assays. n=6. Error bars represent SD. **p,0.01.
doi:10.1371/journal.pone.0015645.g005
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AD. In this regard, NIa could be used as a novel tool to study the
molecular events underlying the induction of cell death by
intracellular Ab. Finally, our results offer proof-of-concept that
the clearance of intracellular Ab by a cytosolic protease could be a
viable strategy for the treatment of AD. To further evaluate the
therapeutic potential of NIa, we are currently performing a series
of behavioral tests on the APPsw/PS1 mice infused with Lenti-NIa.
We observed no apparent cytotoxicity of NIa itself in vitro, but did
not test this issue in vivo. Cleavage of essential cytosolic proteins by
NIa could elicit detrimental results in neuronal cells. It is intriguing
to note that NIa proteases from tobacco etch virus (TEV) and
tomato vein mottling virus (TVMV), the close relatives of TuMV,
are frequently used for removing fusion tags from newly synthesized
recombinant proteins in vitro. It is assumed that these proteases
seldom cleave mammalian proteins due to their high substrate
specificities. Nonetheless, vigorous biochemical and behavioral tests
are warranted to address whether NIa is cytotoxic by itself.
Materials and Methods
Antibodies and reagents
Cell culture reagents were purchased from GIBCO-BRL
(Invitrogen, Carlsbad, CA, USA). Synthetic Ab1242 peptide was
purchased from Sigma (St Louis, MO, USA) and Anygen
(Gwangju, Korea). 6E10 antibody recognizing residues 1217 of
Ab peptide was purchased from Signet
TM (Dedham, MA, USA).
Antibodies against HA, a-tubulin, VDAC2, Oct1, and cathepsin
D were purchased from Abcam (Cambridge, MA, UK). Chitin
beads were purchased from New England BioLabs (Ipswich, MA,
USA). All other reagents were purchased from Sigma.
Purification of the NIa protease
To produce recombinant NIa protein in E. coli, the NIa gene
was cloned into pTYB12 (New England BioLabs) via the EcoRI
and XhoI sites. The pTYB12 vector contains an N-terminal intein
tag. The pTYB12-NIa vector was transformed into the E. coli
strain BL21 (DE3) and grown at 37uC in LB medium. Induction of
the NIa protein was achieved by addition of 400 mM IPTG
overnight at 20uC. The cells were harvested, resuspended in
column buffer (20 mM HEPES [pH 7.9], 500 mM NaCl, 1 mM
EDTA), and lysed by sonication. The lysate was centrifuged
and the resulting supernatant was loaded onto a chitin column
equilibrated with column buffer. After extensive washing, the NIa
protein was eluted from the column using a column buffer
containing 50 mM DTT, dialyzed in storage buffer (50 mM
HEPES [pH 7.6], 1 mM EDTA, 1 mM DTT, 10% glycerol), and
concentrated by Amicon Centriprep (Millipore, Billerica, MA,
USA). The protein concentration was determined by the BCA
method and analyzed on a 12% SDS-PAGE gel.
Ab preparation
To prepare Ab solutions, we followed the method described by
Yan et al.[41] and Dahlgren et al.[3]. Synthetic human Ab1242
peptides (.95% pure by high performance liquid chromatography
and mass spectrometry tests) were dissolved in dimethylsulfoxide
(DMSO) to a concentration of 5 mM. For monomeric Ab, the Ab
solution in DMSO was diluted in PBS to a final concentration of
25 mM immediately before use. For oligomeric Ab, the Ab
solution in DMSO was diluted in PBS to a concentration of
100 mM and incubated at 4uC for 36 hrs. The physical state of Ab
was confirmed by PAGE with 10220% Tris-Tricine gels (Bio-
Rad, Hercules, CA, USA).
Cleavage assays and mass spectrometry
1.5 mM of the recombinant NIa protease was incubated with
2.5 mMA b preparations in an assay buffer (HEPES [pH 7.4],
20 mM KCl, 20 mM MgCl2)a t2 5 uC for 3 hrs. As a control, the
NIa protease was pre-incubated with the cysteine protease
inhibitor, N-ethylmaleimide (NEM) for 10 min at 4uC. After
incubation, the mixtures were subjected to PAGE with 10220%
Tris-Tricine gel and Western blotting using the anti-Ab antibody
6E10. To further analyze the cleavage products, the reaction
mixtures were analyzed by MALDI-TOF/TOF mass spectrom-
etry (4700 Proteomics Analyzer, Applied Biosystems, Carlsbad,
California, USA). As controls, NIa and Ab were separately
analyzed.
Cell culture, transfection and Ab treatment
B103 rat neuroblastoma cells were cultured in DMEM
supplemented with 10% (vol/vol) fetal bovine serum[42]. A
mutant NIa gene in which Asp
81 in the catalytic triad was changed
to Ala was generated by a PCR mutagenesis. To express the wild
type and mutant NIa in B103 cells, the corresponding genes were
subcloned into pcDNA3 (Invitrogen) containing an N-terminal
HA tag. Cells were transfected using Lipofectamine Reagent
(Invitrogen) according to the manufacturer’s protocol. A cytosolic
Ab1242 expression vector (pGFPUb-Ab1242) was previously
described[25]. For the Ab treatment, the Ab solutions (100 mM)
were added to a final concentration of 5 mM.
Assessment of cell death
Cell viability was assessed by MTT assay and cell morphological
methods. The 3-[4,5-dimethylthizaol-2-yl]-2,5-diphenyl tetrazoli-
um bromide (MTT) was solubilized in PBS to 5 mg/ml. A volume
of MTT solution equal to 10% of the culture media volume was
added to the cell culture at 37uC for 3 hrs. A solubilization
solution (10% Triton X-100 and 0.1 N HCl in anhydrous
Figure 6. Lentiviral-mediated expression of NIa. (A) Lentiviral
constructs for the expression of HA-NIa and GFP. (B) Western blotting
with anti-HA antibody showed the NIa expression levels in 293T cells
infected with Lenti-NIa. (C) The brains infused with Lenti-GFP and Lenti-
NIa were subjected to RT-PCR. A PCR product corresponding to NIa was
detected. GAPDH was used as control.
doi:10.1371/journal.pone.0015645.g006
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added and further incubated at 37uC until the resulting formazan
crystals were completely dissolved. The absorbance of the samples
was measured at 570 nm, and the background absorbance of each
well was measured at 690 nm. For the assessment of cell
morphology, cultured cells were co-transformed with the exper-
imental plasmid and a GFP plasmid and the morphology of GFP-
positive cells was examined under a fluorescence microsco-
pe[42](Olympus, Shinjuku, Tokyo, Japan).
Immunofluorescence and confocal microscopy
B103 rat neuroblastoma cells were washed with PBS containing
1 mM CaCl2 and 1 mM MgCl2 and fixed for 10 min with 3.5%
paraformaldehyde. The cells were permeabilized by incubation
with 0.2% Triton X-100 in PBS for 10 min, blocked with 5% BSA
in PBS for 1 hr, and incubated with anti-6E10 monoclonal
antibody or HA monoclonal antibody for 1 hr. The fixed cells
were then rinsed in PBS and incubated with Alexa 488 fluor-
conjugated secondary antibody (Invitrogen) and TRITC-conju-
gated secondary antibody (Jackson Immunoresearch, West Grove,
PA, USA) for 1 hr. For immunofluorescence microscopy,
immunoreactivity was captured with a fluorescence microscope
(Olympus) with a ProgRes C10
pluscamera (JENOPTIK, Goesch-
witzer Strasse, Jena, Germany). Color coding was performed using
the IMT i-solution software (IMT i-solution Inc., Vancouver, BC,
Canada). To determine the levels of Ab aggregation among GFP
positive cells, the number of Ab positive cells vs. GFP positive cells
was counted in 20 random fields per culture. For confocal
microscopy analysis, fluorescence signals were visualized using a
confocal microscope (TCS SP2, LEICA, Ernst-Leitz-Strasse,
Wetzlar, Germany).
Subcellular fractionation
To determine the intracellular localization of the NIa protein,
NIa- expressing cells were fractionated using protocol previously
described[43]. Briefly, the cells were harvested by scraping into
homogenation buffer (200 mM sucrose, 20 mM Tris [pH 7.4],
1 mM EGTA, 1 mM EDTA, 1 X complete protease inhibitor
cocktail), lysed by multiple passages through a syringe with a 26-
gauge needle, and ultracentrifuged at 70,0006g for 30 min at 4uC.
The pellet (crude membrane fraction) was resuspended in
homogenation buffer containing 0.5% Triton X-100 and sonicat-
ed for 1 min. Aliquots (50 mg) from each fraction were analyzed by
Western blotting.
Electrophoresis and Western blotting
The cells were harvested after washing three times with PBS,
resuspended in RIPA buffer containing 1X protease inhibitor
cocktail and sonicated briefly. The soluble protein fraction was
recovered after centrifugation at 10,0006g for 30 min and
separated by SDS–PAGE. Protein concentration was determined
by the BCA method. For the analysis of Ab peptides, samples were
separated by electrophoresis using 10220% Tris-Tricine gels.
Proteins were then transferred onto PVDF membrane in 50 mM
Tris, 192 mM glycine, and 20% methanol. Membranes were
blocked with 5% non-fat milk and incubated with antibodies
against 6E10, HA, a-tubulin, VDAC2, Oct1, and cathepsin D.
Bands were visualized using the ECL reagent (GE Healthcare/
Amersham Bioscience, Piscataway, NJ, USA) and the intensity of
each band was quantified by densitometry (Bio-Rad).
Production of lentiviruses
The cDNA fragments encoding NIa and GFP were subcloned
into the pLEX-MCS lentiviral vector (Openbiosystems, Hunts-
ville, AL,USA). The resulting recombinant plasmids were co-
transformed with packing plasmids into 293T cells and the
supernatants were collected. Lentiviruses were collected and
concentrated by ultra-centrifugation as previously described
[19,44]. The titers of the NIa and GFP lentiviruses were estimated
by measuring the amount of HIV p24 antigen using PCR.
AD murine model and surgical procedure
Transgenic AD model mice, Tg-APPswe/PS1dE9, overexpress-
ing human mutated APP and PS1 (APPswe/PS1dE9), were
maintained in C57BL6 x C3H F1 hybrid mice, as described
previously[45]. The mice were housed in normal plastic cages with
free access to food and water in a temperature- and humidity-
controlled environment under a 12 h light/dark cycle (lights on at
7 a.m.), and they were fed a diet of lab chow and water ad libitum.
Tg-APPswe/PS1dE9 mice at 6.5 months of age were randomized
into the Lenti-NIa (n=9) and Lenti-GFP (n=10) groups. The
mice underwent bilateral intracerebroventricular (i.c.v.) infusion
with 3 ml of Lenti-NIa lentivirus (1610
8 TU) or Lenti-GFP
lentivirus with the same titer. After one month, the injected mice
were sacrificed and perfused with 0.9% saline. The right and left
hemispheres of the brain were used for histological and
biochemical analyses, respectively. All experiments and animal
procedures were approved by the Animal Care and Use
Committee of the Ewha Womans University School of Medicine.
RT-PCR
Total RNA was isolated with TRI reagent (Sigma) from frontal
cerebral cortex tissue. Reverse-transcription was performed using
ImProm II reverse-transcriptase (Promega, Madison, Wisconsin,
USA) with oligo-dT priming. To detect NIa expression, PCR was
performed using the NIa specific primer set: 59-ACG AAA GAC
GGC CAA TGC GGA-39 and 59-ACC CGA CGG TTG CGA
TGC TT-39. And for control experiment, PCR was performed
using the GAPDH specific primer set: 59- TCC GTG TTC CTA
CCC CCA ATG-39 and 59- GGG AGT TGC TGT TGA AGT
CGC-39.
Immunohistochemistry
The right hemisphere was post-fixed with 4% paraformalde-
hyde in 0.1 M phosphate buffer (pH 7.4) at 4uC overnight and
were coronally cut into 40 mm-thick sections with a vibratome
(Leica VT 1000S; Leica, Germany). Free-floating sections were
blocked by 5% normal goat serum, 2% BSA, and 2% FBS. A
biotinylated HRP system was used for color development. Anti-Ab
antibody Bam-10 (A5213) was purchased from Sigma (USA).
Figure 7. NIa-mediated reduction in Ab levels and Ab plaques in APPsw/PS1dE9 mouse brains. (A) Brains of APPsw/PS1dE9 were bilaterally
infused with Lenti-GFP and Lenti-NIa, and the amounts of Ab1240 and Ab1242 were measured by ELISA. The amounts of soluble and insoluble Ab1240
are shown (upper lane). The amounts of soluble and insoluble Ab1242 are shown (lower lane). (B) Sections of prefrontal cortex, parietal cortex,
hippocampus, and piriform cortex of APPsw/PS1dE9 male mouse infused with Lenti-GFP and Lenti-NIa were stained with anti-Ab antibody (Bam-10).
(C) The number of plaques in the prefrontal cortex, parietal cortex, and piriform cortex of APPsw/PS1dE9 male mouse infused with Lenti-GFP and
Lenti-NIa was counted. For Lenti-GFP infusions, n=5 for male and n=5 for female. For Lenti-NIa infusions, n=6 for male and n=3 for female. Error
bars represent SD. *p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0015645.g007
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microscope equipped with a DP71 camera and DP-B software
(Olympus, Japan). For the quantification of plaque levels, the
numbers of plaques in each region were measured using the
TOMORO ScopeEye 3.6 program (Techsan Community, Seoul,
Korea).
Assessment of Ab levels
ELISA assays for Ab (1242) and Ab (1240) levels were
described in a previous study[46]. Briefly, the frontal cerebral
cortex was homogenized in Tris-buffered saline (20 mM Tris and
137 mM NaCl, [pH 7.6]) in the presence of protease inhibitor
mixtures (Complete Mini; Roche, USA). Homogenates were
centrifuged at 100,0006g for 1 hr at 4uC, and the supernatant was
used to measure the levels of Tris buffer-soluble forms of Ab. The
pellet was sonicated in 70% formic acid and centrifuged as above;
the resulting supernatant was considered the formic acid
extractable Ab and collected for further analysis. The formic acid
extract was neutralized with 1 M Tris-Cl buffer (pH 11) in a
dilution ratio of 1:20 before its use as previously described. The
final assays were performed using Human Ab (1240) or Ab
(1242) colorimetric sandwich ELISA kits (BioSource, Invitrogen)
by following the manufacturer’s instructions.
Statistical analysis
Two sample-comparisons were carried out using the unpaired
Student’s t test with unequal variance, while multiple comparisons
were made by one-way ANOVA followed by the Newman-Keuls
multiple range test. A p value of less than 0.05 was accepted as
being statistically significant. Data are presented as mean6SD.
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